NO992336L - Raf-kinase-inhibitorer - Google Patents

Raf-kinase-inhibitorer

Info

Publication number
NO992336L
NO992336L NO992336A NO992336A NO992336L NO 992336 L NO992336 L NO 992336L NO 992336 A NO992336 A NO 992336A NO 992336 A NO992336 A NO 992336A NO 992336 L NO992336 L NO 992336L
Authority
NO
Norway
Prior art keywords
methylphenyl
cyclohexylpropionylamino
acetoxybenzamide
hydroxybenzamide
raf kinase
Prior art date
Application number
NO992336A
Other languages
English (en)
Other versions
NO992336D0 (no
Inventor
Phillip John Hedge
Francis Thomas Boyle
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO992336D0 publication Critical patent/NO992336D0/no
Publication of NO992336L publication Critical patent/NO992336L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Den foreliggende oppfinnelse vedrører farmasøytiske blandinger omfattende inhibitorer av raf-kinase med formel (l), hvori: R1 og R2 er substituenter på fenylringene; p, som kan ha de samme eller forskjellige verdier for R1 og R2, skal være 0-3, og når p er 2 eller 3, kan gruppene være de samme eller forskjellige; R3 er CMalkyl; q er 0-4; R4 er aryl eller cykloalkyl, hvori R4 eventuelt er substituert med opp til 3 subsituenter eller et farmasøytisk akseptabelt salt eller en in vivo hydrolyserbar ester derav og en farmasøytisk akseptabel bærer, under den forutsetning at N-[5-(3-cykloheksyl-propionylamino)-2-metylfenyl]-4-hydroksybenzamid, N-[5-(3-cyklopentylpropionylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(3-fenylpropionylamino)-2-metylfeny!]-4-acetoksybenzamid, N-[5-(4-cykloheksylbutyrylamino)-2-metylfenyl]-4-acetoksybenzamid, N-[5-(2-cykloheksylacetylamino)-2-metylfenyl]-acetoksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-aminobenzamid, Nt[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-nitrobenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksymetylbenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-metoksykarbonyl-benzamid, N-[5-(3-cykloheksylpropionylamino)2-metylfenyl]-2-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-3-hydroksybenzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-benzamid, N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-acetoksybenzarnidog N-[5-(3-cykloheksylpropionylamino)-2-metylfenyl]-4-hydroksybenzamider utelukket. Fremgangsmåter for deres fremstilling og deres anvendelse som terapeutiske midler. EEn spesiell anvendelse er i kreftterapi.
NO992336A 1996-11-16 1999-05-14 Raf-kinase-inhibitorer NO992336L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623833.2A GB9623833D0 (en) 1996-11-16 1996-11-16 Chemical compound
PCT/GB1997/003102 WO1998022103A1 (en) 1996-11-16 1997-11-12 Raf kinase inhibitors

Publications (2)

Publication Number Publication Date
NO992336D0 NO992336D0 (no) 1999-05-14
NO992336L true NO992336L (no) 1999-05-14

Family

ID=10803023

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992336A NO992336L (no) 1996-11-16 1999-05-14 Raf-kinase-inhibitorer

Country Status (8)

Country Link
EP (1) EP0941084A1 (no)
JP (1) JP2001504478A (no)
AU (1) AU4956297A (no)
CA (1) CA2267782A1 (no)
GB (1) GB9623833D0 (no)
NO (1) NO992336L (no)
WO (1) WO1998022103A1 (no)
ZA (1) ZA9710314B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1999015164A1 (en) 1997-09-23 1999-04-01 Zeneca Limited Amide derivatives for the treatment of diseases mediated by cytokines
DE69834842T2 (de) * 1997-12-22 2007-05-10 Bayer Pharmaceuticals Corp., West Haven Hemmung von raf-kinase unter verwendung von aryl- und heteroarylsubstituierten heterocyclischen harnstoffen
CZ299156B6 (cs) * 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
SK286123B6 (sk) 1998-05-15 2008-04-07 Astrazeneca Ab Benzamidové deriváty, spôsob ich prípravy, farmaceutická kompozícia a ich použitie na prípravu liečiva na liečenie chorôb sprostredkovaných cytokínmi
PT1077930E (pt) * 1998-05-15 2005-03-31 Astrazeneca Ab Derivados de benzamida para o tratamento de doencas mediadas por citocinas
JP2002522421A (ja) 1998-08-04 2002-07-23 アストラゼネカ アクチボラグ サイトカイン産生の阻害剤として有用なアミド誘導体
ID28267A (id) 1998-09-25 2001-05-10 Astrazeneca Ab Turunan benzamida dan penggunaannya sebagai inhibitor sitokina
EP1117653B1 (en) 1998-10-01 2003-02-05 AstraZeneca AB Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases
AU6513199A (en) 1998-10-09 2000-05-01 Anadys Pharmaceuticals, Inc. Aryldiamine derivatives useful as antibacterial agents
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Corporation .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
BR0009083B1 (pt) 1999-03-17 2011-11-01 derivado de amida compreendendo um núcleo de quinazolinona, processo para a preparação de um derivado de amida, composição farmacêutica, e, uso de um derivado de amida.
JP2002539187A (ja) 1999-03-17 2002-11-19 アストラゼネカ アクチボラグ アミド誘導体
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
JP4643909B2 (ja) * 2001-12-21 2011-03-02 ザ ウェルカム トラスト リミテッド 遺伝子
WO2003068746A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
WO2004064733A2 (en) * 2003-01-15 2004-08-05 Board Of Regents, University Of Texas System The use of c-raf inhibitors for the treatment of neurodegenerative diseases
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
US7691870B2 (en) 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
WO2006007520A1 (en) * 2004-07-01 2006-01-19 Wisconsin Alumni Research Foundation Hydroxybenazamide compounds for treatment of cancer
CN101010303A (zh) * 2004-09-01 2007-08-01 阿斯利康(瑞典)有限公司 喹唑啉酮衍生物和它们作为b－raf抑制剂的用途
WO2006067445A2 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CA2594860A1 (en) * 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
US8101610B2 (en) 2005-11-14 2012-01-24 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
MX2009011343A (es) 2007-04-20 2009-11-05 Deciphera Pharmaceuticals Llc Inhibidores quinasa utiles para el tratamiento de enfermedades mieloproliferativas y otras enfermedades proliferativas.
CA2798143A1 (en) * 2010-05-11 2011-12-15 Mahesh Kandula Compound, synthesis, composition and uses thereof
US9198911B2 (en) 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
CN103764623B (zh) 2011-08-29 2016-04-27 提克纳有限责任公司 芳族酰胺化合物
US9045685B2 (en) 2011-08-29 2015-06-02 Ticona Llc Cast molded parts formed from a liquid crystalline polymer
JP2014525498A (ja) 2011-08-29 2014-09-29 ティコナ・エルエルシー 高流動性液晶ポリマー組成物
WO2013032981A1 (en) 2011-08-29 2013-03-07 Ticona Llc High flow liquid crystalline polymer composition
US9074133B2 (en) 2011-08-29 2015-07-07 Ticona Llc Thermotropic liquid crystalline polymer with improved low shear viscosity
US8906258B2 (en) 2011-08-29 2014-12-09 Ticona Llc Heat-resistant liquid crystalline polymer composition having a low melting temperature
CN103764741B (zh) 2011-08-29 2015-09-23 提克纳有限责任公司 低熔体粘度液晶聚合物的熔融聚合
WO2013032971A1 (en) 2011-08-29 2013-03-07 Ticona Llc Melt-extruded substrate for use in thermoformed articles
PL2830662T3 (pl) 2012-03-29 2019-02-28 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2014130275A2 (en) 2013-02-22 2014-08-28 Ticona Llc High performance polymer composition with improved flow properties
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
CA3089630A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
DK4084778T3 (da) 2019-12-30 2023-12-11 Deciphera Pharmaceuticals Llc Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004170A1 (en) * 1991-08-23 1993-03-04 The United States Of America Represented By The Secretary, Department Of Health And Human Services Raf protein kinase therapeutics

Also Published As

Publication number Publication date
AU4956297A (en) 1998-06-10
EP0941084A1 (en) 1999-09-15
JP2001504478A (ja) 2001-04-03
NO992336D0 (no) 1999-05-14
GB9623833D0 (en) 1997-01-08
ZA9710314B (en) 1998-05-18
WO1998022103A1 (en) 1998-05-28
CA2267782A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
NO992336L (no) Raf-kinase-inhibitorer
DE69918404D1 (de) Aminophenoxyessigsäure derivate als neuroschützende mittel
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
DE69921804D1 (de) Benzamid-derivate zur behandlung cytokin-vermittelter krankheiten
HUP0104060A2 (hu) Benzamid-származékok és felhasználásuk citokin-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BG93979A (bg) Производни на n-(4-пиперидинил)(дихидробензофуран или дихидро-2н-бензопиран)карбоксамид, фармацевтичен състав, който ги съдържа, метод за получаване на производните и приложението им
RU95108387A (ru) Дикетопиперазин, способ его получения, фармацевтическая композиция, применение дикетопиперазина
EE03435B1 (et) Maatriksmetalloproteaasi inhibeeriva aktiivsusega ühendid, nende valmistamismeetodid ja kasutamine, vaheprodukt ja kompositsioon
RU95108243A (ru) Производные амидов вальпроновой и 2-вальпроеновой кислоты, фармацевтическая композиция, способы лечения
EE03139B1 (et) Piperasiiniderivaadid, nende kasutamine ja farmatseutiline kompositsioon
HUP0002272A2 (hu) Piperazinszármazékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
DZ1694A1 (fr) "n-(2-Aminoethyl)-benzothialozones".
HUP0100558A2 (hu) S-Oxid- és S,S-dioxid-tetrahidrotiopirán-fenil-oxazolidinon-származékok, e vegyületek alkalmazása gyógyászati készítmények előállítására, valamint eljárás e vegyületek gátló hatásának meghatározására humán-monoamin-oxidázzal szemben
RU95105435A (ru) N-замещенные производные 3-азабицикло [3.2.0]гептана в качестве нейролептического средства
WO2003082861A3 (en) Morpholinyl-urea derivatives for use of the treatment of inflammatory diseases
ATE153666T1 (de) Phosphono-arylethanolamin-verbindungen mit antihyperglykämischer und/oder antiobeser wirkung
ATE270550T1 (de) Wirkstoff zum schutz für organ oder gewebe
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
UA49005C2 (uk) Похідні камптотецину (варіанти), спосіб їх одержання (варіанти) та фармацевтична композиція на їх основі
HUT52106A (en) Process for producing beta-delta-phenylthioxylosides and pharmaceutical compositions comprising such compounds as active ingredient
BG88028A (bg) Амиди на циклометилен-1,2-дикарбоксилни киселини с терапевтична активност,методи за получаването им и фармацевтични състави, които ги съдържат
DE69330601D1 (de) Serotoninergische ergolin derivate
ES8300095A1 (es) "un procedimiento para preparar derivados de halofenil-piridil-alilamina".
RU95104890A (ru) Новые стероиды, содержащие в положении 20 аминозамещенную цепь, метод и промежуточные продукты подготовки данного метода, их применение в качестве медикаментов и включающие их фармацевтические соединения
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application